Propel previously shared a billing code with Intersect ENT’s Sinuva implant, the release said. The new approval establishes a separate code for Propel and updates Sinuva’s J-Code to J7402.
Propel products are the first and only bioabsorbable steroid-releasing sinus implants approved by the FDA to maintain patency and locally deliver steroids to adults after sinus surgery, the release said.
More articles on healthcare:
Ophthalmologist convicted of $73M billing fraud has 17-year sentence commuted by Trump
What hospitals posting rates online means for ASCs
Optum reports revenue of $35.9B in Q4, $136.3B in 2020 — 6 insights
